Josh Hattem co-wrote this blog post with Emily Mandell.
“That's the problem with the American dream: It makes everyone concerned for the day they're gonna be rich.”
–President Bartlett, The West Wing
Pharma companies may have a winning asset, a winning development plan and an important disease target with unmet needs, but only one product can be first to market, only one can be the most efficacious and only one will become the standard of care. If your asset is entering a disease area with similar efficacy to an established standard of care, or if your asset is one of multiple products in a class entering within one to two years of one another, it’s critical to have a clear understanding of what it will take to meaningfully differentiate, and to do this early enough—in phase I or II—so there's enough time to correct the development plan.